Citalopram may increase the hyponatremic activities of Chlorthalidone. The risk or severity of adverse effects can be increased when Metaxalone is combined with Citalopram. The serum concentration of Topotecan can be increased when it is combined with Citalopram. Normethadone may increase the serotonergic activities of Citalopram. The metabolism of Dexchlorpheniramine maleate can be decreased when combined with Citalopram. The risk or severity of adverse effects can be increased when Norflurane is combined with Citalopram. The metabolism of Citalopram can be decreased when combined with Itraconazole. The risk or severity of adverse effects can be increased when Triprolidine is combined with Citalopram. The metabolism of Pentoxifylline can be decreased when combined with Citalopram. Palonosetron may increase the serotonergic activities of Citalopram. Heroin may increase the serotonergic activities of Citalopram. The metabolism of Tamsulosin can be decreased when combined with Citalopram. The risk or severity of adverse effects can be increased when Proparacaine is combined with Citalopram. The metabolism of Ethylmorphine can be decreased when combined with Citalopram. The serum concentration of Citalopram can be increased when it is combined with Ketoconazole. The risk or severity of QTc prolongation can be increased when Citalopram is combined with Pimozide. The risk or severity of adverse effects can be increased when Tetracaine is combined with Citalopram. The risk or severity of adverse effects can be increased when Brotizolam is combined with Citalopram. The metabolism of Rupatadine can be decreased when combined with Citalopram. The metabolism of Propranolol can be decreased when combined with Citalopram. The serum concentration of Agomelatine can be increased when it is combined with Citalopram. The metabolism of Citalopram can be decreased when combined with Telaprevir. The metabolism of Methyprylon can be decreased when combined with Citalopram. Levomethadyl Acetate may increase the serotonergic activities of Citalopram. The risk or severity of adverse effects can be increased when Methylecgonine is combined with Citalopram. The serum concentration of Citalopram can be increased when it is combined with Propafenone. The metabolism of Fluorouracil can be decreased when combined with Citalopram. The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Citalopram. The metabolism of Citalopram can be increased when combined with Nevirapine. The metabolism of Pomalidomide can be decreased when combined with Citalopram. The risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Citalopram. The metabolism of Tetrabenazine can be decreased when combined with Citalopram. The metabolism of Buprenorphine can be decreased when combined with Citalopram. The metabolism of Citalopram can be decreased when combined with Terbinafine. Indapamide may increase the QTc-prolonging activities of Citalopram. The risk or severity of adverse effects can be increased when Lorazepam is combined with Citalopram. Butorphanol may increase the serotonergic activities of Citalopram. The metabolism of Citalopram can be decreased when combined with Cyclosporine. The risk or severity of adverse effects can be increased when Loprazolam is combined with Citalopram. The risk or severity of adverse effects can be increased when Citalopram is combined with Tiapride. Citalopram may increase the hypoglycemic activities of Insulin Human. The metabolism of Anagrelide can be decreased when combined with Citalopram. The risk or severity of adverse effects can be increased when Zaleplon is combined with Citalopram. Dolasetron may increase the serotonergic activities of Citalopram. The risk or severity of adverse effects can be increased when Flibanserin is combined with Citalopram. Etorphine may increase the serotonergic activities of Citalopram. The metabolism of Debrisoquin can be decreased when combined with Citalopram. Iproclozide may increase the serotonergic activities of Citalopram. The risk or severity of adverse effects can be increased when Citalopram is combined with Benperidol. The metabolism of Ospemifene can be decreased when combined with Citalopram. The risk or severity of adverse effects can be increased when Gepirone is combined with Citalopram. The metabolism of Bufuralol can be decreased when combined with Citalopram. The risk or severity of adverse effects can be increased when Ethotoin is combined with Citalopram. The risk or severity of adverse effects can be increased when Tandospirone is combined with Citalopram. The risk or severity of adverse effects can be increased when Citalopram is combined with Harmaline. The serum concentration of Citalopram can be increased when it is combined with Stiripentol. Dextromoramide may increase the serotonergic activities of Citalopram. The serum concentration of Citalopram can be increased when it is combined with Delavirdine. The metabolism of Nitrofural can be decreased when combined with Citalopram. The serum concentration of Citalopram can be increased when it is combined with Palbociclib. Citalopram may increase the hypoglycemic activities of Pioglitazone. The metabolism of Amphetamine can be decreased when combined with Citalopram. The metabolism of Betaxolol can be decreased when combined with Citalopram. The serum concentration of Prucalopride can be increased when it is combined with Citalopram. The metabolism of Hexobarbital can be decreased when combined with Citalopram. The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Citalopram. The metabolism of Carvedilol can be decreased when combined with Citalopram. The metabolism of Tacrolimus can be decreased when combined with Citalopram. Maprotiline may increase the QTc-prolonging activities of Citalopram. Ritonavir may increase the QTc-prolonging activities of Citalopram. Diphenhydramine may increase the QTc-prolonging activities of Citalopram. The risk or severity of adverse effects can be increased when Thiopental is combined with Citalopram. The metabolism of Chlorpromazine can be decreased when combined with Citalopram. The risk or severity of adverse effects can be increased when Levocabastine is combined with Citalopram. Citalopram may increase the serotonergic activities of Alaproclate. The risk or severity of adverse effects can be increased when Allopregnanolone is combined with Citalopram. The risk or severity of bleeding can be increased when Betrixaban is combined with Citalopram. The risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Citalopram. The metabolism of Levodopa can be decreased when combined with Citalopram. Ciprofloxacin may increase the QTc-prolonging activities of Citalopram. The serum concentration of Citalopram can be decreased when it is combined with Enzalutamide. Citalopram may increase the hyponatremic activities of Methyclothiazide. The metabolism of Methylphenidate can be decreased when combined with Citalopram. Citalopram may increase the hypoglycemic activities of Repaglinide. The metabolism of Benzatropine can be decreased when combined with Citalopram. Arformoterol may increase the QTc-prolonging activities of Citalopram. The metabolism of Erlotinib can be decreased when combined with Citalopram. The metabolism of Progesterone can be decreased when combined with Citalopram. Alphacetylmethadol may increase the serotonergic activities of Citalopram. The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Citalopram resulting in a loss in efficacy. The risk or severity of adverse effects can be increased when Opipramol is combined with Citalopram. The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Citalopram. The metabolism of Prochlorperazine can be decreased when combined with Citalopram. Citalopram may increase the antiplatelet activities of Valdecoxib. The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Citalopram. The risk or severity of adverse effects can be increased when Pizotifen is combined with Citalopram. The risk or severity of adverse effects can be increased when BL-1020 is combined with Citalopram. Lapatinib may increase the QTc-prolonging activities of Citalopram. The metabolism of Dasabuvir can be decreased when combined with Citalopram. The risk or severity of adverse effects can be increased when Vigabatrin is combined with Citalopram. The risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Citalopram. The metabolism of Dapagliflozin can be decreased when combined with Citalopram. The metabolism of Zidovudine can be decreased when combined with Citalopram. Sunitinib may increase the QTc-prolonging activities of Citalopram. The metabolism of Adinazolam can be decreased when combined with Citalopram. The metabolism of Citalopram can be decreased when combined with Cocaine. Iproniazid may increase the serotonergic activities of Citalopram. The serum concentration of Pirfenidone can be increased when it is combined with Citalopram. The metabolism of Diclofenac can be decreased when combined with Citalopram. The metabolism of Brompheniramine can be decreased when combined with Citalopram. The metabolism of Cephalexin can be decreased when combined with Citalopram. The serum concentration of Citalopram can be increased when it is combined with Cimetidine. The metabolism of Grepafloxacin can be decreased when combined with Citalopram. Caroxazone may increase the serotonergic activities of Citalopram. The risk or severity of adverse effects can be increased when Citalopram is combined with Cyamemazine. Lenvatinib may increase the QTc-prolonging activities of Citalopram. The risk or severity of adverse effects can be increased when Citalopram is combined with Frovatriptan. The serum concentration of Cilostazol can be increased when it is combined with Citalopram. The serum concentration of Citalopram can be increased when it is combined with Fosaprepitant. The metabolism of Rotigotine can be decreased when combined with Citalopram. The risk or severity of adverse effects can be increased when Drotebanol is combined with Citalopram. Lofentanil may increase the serotonergic activities of Citalopram. Citalopram may increase the hypoglycemic activities of Exenatide. The serum concentration of Nebivolol can be increased when it is combined with Citalopram. The risk or severity of adverse effects can be increased when Imipramine is combined with Citalopram. The risk or severity of adverse effects can be increased when Citalopram is combined with Aceprometazine. Etoperidone may increase the serotonergic activities of Citalopram. The metabolism of Domperidone can be decreased when combined with Citalopram. The metabolism of Vinblastine can be decreased when combined with Citalopram. The metabolism of Valproic Acid can be decreased when combined with Citalopram.